10/568261

@PFDesktop\::ODMA/MHODMA/HBSR05;iManage;604783;1 2/10/06

under 37 CFR 1.97(i):

(Filed after payment of issue fee)

filewrapper.

[ ]

### DOCKET NO.: 3593.1000-003 IAP9 Rec'd PCT/PTO 13 FEB 2006

#### IN THE UNITED STATES RECEIVING OFFICE (RO/US) Designated/Elected Office (DO/EO/US)

U.S. National Stage International App	e of plication No.:	PCT/US2004/026359		
International Filing Date:		13 August 2004		
Earliest Priority Da	ite:	13 August 2003		
Applicant:		Gordon D. Ross (deceased)		
Title:		EFFECT OF BETA-GLUCAN ON STEM CELL RECRUITMENT AND TISSUE REPAIR		
Attorney's Docket 1	No.:	3593.1000-003		
		Date: 13 February 2004		
	EXPRESS MA	IL LABEL NO. <u>E V 21488722945</u>		
<u>L.</u>				
	INFORM	AATION DISCLOSURE STATEMENT		
Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450				
Sir:				
This Information Disclosure Statement is submitted:  [ ] under 37 CFR 1.129(a), or  (First/Second submission after Final Rejection)				
[X] under 37 CFR 1.97(b), or  (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).				
[ ] under 37	] under 37 CFR 1.97(c) together with either:			
[ ] a	[ ] a Statement under 37 CFR 1.97(e), as checked below, or			
[ ] a (After the 37	[ ] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)			
	CFR 1.97(d) togeth			
[ ] a	Statement under 37	7 CFR 1.97(e), as checked below, and		
[ ] a	\$180.00 fee under	37 CFR 1.17(p), or ance, whichever occurs first, but on or before payment of the issue fee)		

Applicant requests that the IDS and cited reference(s) be placed in the application

### Statement Under 37 CFR 1.97(e) Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. Statement Under 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000 [ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. Enclosed herewith is form PTO-1449: [ X ] Copies of the cited references are enclosed. [X] Copies of issued U.S. patents and published U.S. applications are not required and are not being provided. Copies of the cited references are enclosed except those entered in prior application, U.S. Application No. [ ], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.] The listed references were cited in the enclosed International Search Report in a [X]counterpart foreign application. [ ] The "concise explanation" requirement (non-English references) for reference(s) [ under 37 CFR 1.98(a)(3) is satisfied by: the explanation provided on the attached sheet. the explanation provided in the Specification. submission of the enclosed International Search Report. submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action. [ ]

the enclosed English language abstract.

10/568261 IAP9 Rec'd PCT/PTO 13 FEB 2006

[ ]	App	licant requests that the following r	non-published pending application	cations be considered:
Examiner's Initials				
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		U.S. Patent Application No. [	], by [inventor(s)], filed [	], Docket No.: [ ]
		Examiner	Date	_
	[ ]	A copy of each above-cited appearant application filed on the PTO's Image File Wrapper	or after June 30, 2003, which	th has been scanned into
	[ ]	A copy of each above-cited appearance of those entered in prior appriority under 35 U.S.C. 120 is	oplication, U.S. Application	
		ner is requested to return a copy of were considered with the next office		plications indicating which
It is re	quest	ed that the information disclosed h	nerein be made of record in the	his application.
Metho	d of p	payment:		
[ ]		neck for the fee noted above is encaccompanying Reply. A copy of the		cluded in the check with
[ ]		se charge Deposit Account 08-038 aclosed.	30 in the amount of \$[	. A copy of this Statement
[X]	Plea	se charge any deficiency in fees ar	nd credit any overpayment to	Deposit Account 08-0380.
		I	Respectfully submitted,	
			HAMILTON, BROOK, SMI By Alice O. Carroll Registration No.: 33,542 Telephone: (978) 341-0036 Fractionile: (978) 341-0136	<del> </del>

Concord, MA 01742-9133 Dated: February 13, 2006

IAP9 Rec'd PCT/PTO 13 FEB 2006

				Sheet I di
PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3593.1000-003		APPLICATION 568261	
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION	FIRST NAMED INVENTOR Gordon D. Ross (deceased)  FILING DATE			
February 13, 2006  (Use several sheets if necessary)	EXAMINER	CONFI	RMATION NO.	GROUP

U.S. PATENT DOCUMENTS						
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT		
D.A.D.	A1	6,713,459 B1	03-30-2004	Williams et al.		
D.A.D.	A2	5,504,079	04-02-1996	Jamas et al.		
	A3					
	A4					
	A5					
	A6					
	A7					
	A8					
	A9					
	A10					
	All					
	A12					
	A13					
	A14	· · · · · · · · · · · · · · · · · · ·				
	A15					
	A16					
	A17					
	A18					
	A19					
	A20	<del></del>				
	A21					
	A22					
	A23					
	A24	-				
	A25					

EXAMINER	DATE CONSIDERED
/Deborah A. Davis/	/5-25/10/
	L

# IAP9 Recarditatu 13 FEB 2005

PTO-1449 REPRODUCED

#### INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

February 13, 2006

(Use several sheets if necessary)

			Sheet 2 of 3	
ATTORNEY DOCKET NO. 3593.1000-003		10/568261		
FIRST NAMED INVENTOR Gordon D. Ross (deceased)		FILING DATE		
EXAMINER		RMATION NO.	GROUP	

FOREIGN PATENT DOCUMENTS					
	DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO	
D.A.D. BI	WO 2004/014320 A2	02-19-2004	Biopolymer Engineering, Inc.		
B2					
B3					
B4				-	
B5					
Ве		-			
В7	,	_			
B8					
B9			·		
Bı	0				
Bi	1				
B1	2				
Bi	3				
Bi	4				
Bi	5				
В	6				
В	7				
В	8				
В	9				
B	20				
Bí	21				
B	22				
B	23				
B	24				

EXAMINER	/Deborah A. Davis/	DATE CONCERNIE /5-25-10/

IAPO Rac'd PCT/PTO 13 FEB 2006

PTO-1449 REPRODUCED

## INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION

February 13, 2006

(Use several sheets if necessary)

ATTORNEY DOCKET NO. 3593.1000-003

APPLIADY 568261

FIRST NAMED INVENTOR
Gordon D. Ross (deceased)

FILING DATE

EXAMINER

CONFIRMATION NO.

GROUP

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
D.A.D.	C1	Patchen, et al., "Stimulated Hemopoiesis and Enhanced Survival Following Glucan Treatment in Sublethally and Lethally Irradiated Mice", Int. J. Immunopharmac., 7(6):923-932 (1985).			
	C2	Patchen et al., "Soluble Polyglycans Enhance Recovery from Cobalt-60-Induced Hemopoietic Injury", J. Bioligical Response Modifiers, 3:627-633 (1984).			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	C3	Li, Chuanfu et al., "(1-3)-β-D-Glucan Reduces Infarct Size in Rat Hearts: Correlated with Blunting of NF-κB Activation", Annual Meeting of the Federation of American Societies for Experimental Biol.; Orlando, FL, 15(5):A1140, Abstract XP009052145 (8 March 2001).			
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	C4	Li, Yuehua et al., "Modulating Toll-like Receptor Signaling by (1-3)-beta-D-Glucan Rapidly Induces Cardioprotection from Ischemic Injury", FASEB Meeting on Experimental Biology: Translating the Genome; San Diego, CA, 17(4-5): Abstract XP002339761 (March 2003).			
	C5	Cramer <i>et al.</i> , "Role of the Complement System and LPS in Bone Marrow Repair After Myclotoxic Injury", <i>Molecular Immunology</i> , 41(2-3):223-224, Abstract (June 2004).			
	C6	Ross et al., "Newly Identified Function for the Complement (C) System in Regulating Mematopoiesis and Bone Marrow Reconstitution After Radiation Injury", Experimental Hematology, 31(7):235-236, Abstract XP-002339757 (July 2003).			
	C7				
	C8				
	C9				
	C10				
	C11				
	C12				
	C13				
	C14				

EXAMINER //Deborah A. Davis/	DATE CONSIDERED	/5-25-10/